Search Clinical Trials in the European Union

3-6 months
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
21-40 of 331 trials

Asthma Treatment: Povorcitinib Study

We are evaluating a new medication for adults with moderate to severe asthma that isn't well controlled. The study aims to see if it improves lung function and reduces asthma attacks.

Asthma3-6 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Early-Stage Breast Cancer: Long-Term Follow-Up Study

We are examining the long-term health of early-stage breast cancer patients from previous studies. This research will help us understand relapse rates and overall survival.

Early Stage Invasive Breast Cancer3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesOncology

Follicular Lymphoma: Radiotherapy with Obinutuzumab

We are studying whether adding Obinutuzumab to local radiotherapy improves outcomes for patients with early-stage Follicular Lymphoma. This trial will help us understand the effectiveness and safety of this combination treatment.

Early Stage Follicular Lymphoma3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Diffuse Large B-Cell Lymphoma: Odronextamab vs. Rituximab

We are studying how well odronextamab combined with chemotherapy works compared to rituximab with chemotherapy in patients who have not yet received treatment for diffuse large B-cell lymphoma. The trial aims to evaluate safety and effectiveness in this patient group.

Diffuse Large B-cell Lymphoma3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Actinic Keratosis: Sinecatechins Ointment Study

We are studying a green tea extract ointment for adults with actinic keratosis on the scalp and face. The goal is to see if it clears skin lesions better than a placebo and to assess its safety.

Actinic Keratosis3-6 monthsConfirmation phase (III)≤5 visitsInvestigational MedicinesDermatology

Pulmonary Sarcoidosis: XTMAB-16 Treatment Study

We are testing a new treatment called XTMAB-16 for people with pulmonary sarcoidosis to see if it can safely reduce the need for corticosteroids. This study will help determine the best dose and assess its effectiveness.

Pulmonary Sarcoidosis3-6 monthsSafety phase (I)Efficacy phase (II)>20 visitsInvestigational MedicinesInternal MedicinePulmonology

Prostate Cancer: AAA617 Treatment Study

We are studying a new drug, AAA617, for adult men with oligometastatic prostate cancer to see if it can delay disease progression compared to standard observation. This trial aims to evaluate its effects on survival and quality of life.

Oligometastatic Prostate Cancer3-6 monthsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Rheumatoid Arthritis: LY3871801 Study

We are testing a new medication, LY3871801, for adults with moderately-to-severely active rheumatoid arthritis. The study aims to see if it can reduce disease activity better than a placebo.

Rheumatoid Arthritis3-6 monthsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Hearing Loss Prevention: Sodium Thiosulfate for Chemotherapy Patients

We are studying whether transtympanic sodium thiosulfate can help prevent hearing loss in patients receiving cisplatin chemotherapy. This trial will compare its effects on hearing with those of untreated ears.

Head and Neck Cancer3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesOncologyOtolaryngology

Fish Oil for Recovery in High-Risk Heart Surgery Patients

We are studying whether an intravenous fish oil treatment can prevent atrial fibrillation and improve recovery in patients undergoing high-risk cardiac surgery. This trial compares the fish oil treatment to a placebo.

Critical Illness3-6 monthsEfficacy phase (II)Investigational MedicinesCardiologyInternal Medicine

Alpha-1 Antitrypsin Deficiency: Fazirsiran Treatment Study

We are investigating the long-term safety of fazirsiran for people with liver disease related to Alpha-1 Antitrypsin Deficiency. The study will also look at how this treatment affects liver health over time.

Alpha-1 Antitrypsin Deficiency3-6 monthsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHepatologyPulmonology

Staphylococcus aureus Bacteremia: SNAP Trial

We are testing various treatment options for patients with Staphylococcus aureus bacteremia to see how they impact survival and other health outcomes. This study aims to improve care for those affected by this serious infection.

Staphylococcus aureus Bacteremia3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Cardiogenic Shock: Early Empagliflozin Treatment

We are studying if starting empagliflozin early helps patients with cardiogenic shock improve their heart function and reduce hospital visits. This trial compares the new treatment with standard care to see which is more effective.

Cardiogenic Shock3-6 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Acute Brain Injury: Apomorphine and Psilocybin Study

We are exploring the safety of two medications in patients who are unresponsive in the ICU due to brain injury. The goal is to find effective doses while monitoring for any side effects.

Coma and Disorders of Consciousness3-6 monthsSafety phase (I)Investigational MedicinesNeurologyPsychiatry

Progressive Pulmonary Fibrosis: FAPI-PET Imaging Study

We are exploring if a special imaging method can help identify the type of lung condition in patients with progressive pulmonary fibrosis. This may improve how we understand and treat their disease.

Progressive Pulmonary Fibrosis3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPulmonology

Preventing Hearing Loss: ACOU085 for Testicular Cancer Patients

We are studying whether ACOU085 can help prevent hearing loss in testicular cancer patients undergoing treatment with cisplatin. The trial will assess the safety and effectiveness of this treatment through ear injections.

Sensorineural Hearing Loss3-6 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesOncologyOtolaryngology

Severe Epilepsy: Cannabidiol Oral Solution

We are studying whether Cannabidiol can help reduce seizures in children and young adults with rare disease-related severe epilepsy. The trial also looks at safety and how it interacts with current medications.

Epilepsy3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesNeurologyPediatrics

Parkinson's Disease: Safinamide vs. Rasagiline for Fatigue

We are studying whether Safinamide or Rasagiline can help reduce fatigue in people with Parkinson's Disease already on stable treatment. The trial will also monitor safety and side effects over six months.

Fatigue in Parkinson's Disease3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteNeurology

Relatlimab and Nivolumab for Young Lymphoma Patients

We are studying a combination of two medications for children and young adults with recurrent or hard-to-treat Hodgkin and Non-Hodgkin lymphoma. The goal is to understand their safety and how well they may work.

Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncologyPediatrics

Gastroparesis: Tradipitant Safety Study

We are evaluating the safety of a new medication, tradipitant, for patients with gastroparesis. The study also looks at how well it may help reduce symptoms and improve quality of life.

Gastroparesis3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyGastroenterology